Pelvic inflammatory disease
Conditions
Interventions
Control Group:Fuyanshu capsule
Intervention Group:Fuyanshu capsule+TEAS+transvaginal electrical stimulation
Sponsors
Suzhou Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. 18 to 50 years old (including 18 and 50 years old) married or unmarried women who have sexual life. 2. In line with the western medical diagnostic criteria of SPID-CPP: (1). History: A previous history of pelvic inflammatory disease with acyclic pain in the pelvic or lower abdomen lasting more than 6 months. (2).Symptoms: persistent discomfort, soreness or pain of the lower abdomen, or accompanied by lumbosacral soreness, which may progress due to heavy work, menstruation or exposure to cold. (3). Essential Physical Signs: Pelvic examination suggests uterine adhesion fixation or limited movement with tenderness, tenderness in the adnexal area or palpable patchy, cord-like thickening or mass. (4). Ancillary methods: Routine blood test, erythrocyte sedimentation rate, vaginal secretion examination, C-reactive protein, CA125 and B ultrasound may change. According to the main symptoms, essential physical signs, combined with the medical history and ancillary methods to make a diagnosis. 3. Conform to the syndrome of qi stagnation and blood stasis: (1). Main symptoms: stabbing pain or distending pain in the lower abdomen or lumbosacral region, which was localized and may sharpen during menstruation. (2). Secondary symptoms: menostaxis, menorrhea, menstrual clot, dark red color of menstrual blood, distending pain of chest and hypochondrium, distending pain of breast, leukorrhagia accompanied by yellow or white color. (3). Tongue manifestation and pulse taking: dark red color of tongue or accompanied by ecchymosis or petechia, String-Tight Pulse or accompanied by hesitant pulse. It is necessary to have 2 primary symptoms and 3 secondary symptoms to be diagnosed. 4. Volunteer to participate in the trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Do not meet the inclusion criteria. (2) Women planning to have a baby, pregnancy or breastfeeding. (3) Vaginitis, acute cervicitis, or pelvic inflammatory disease in the acute stage. (4) Chronic pelvic pain caused by other causes, such as endometriosis, ovarian cysts, reproductive tract malformations, etc. (5) Patients with heart pacemakers implanted in their bodies. (6) Complicated with serious primary diseases of hematopoietic system, cardiovascular system, liver or kidney. (7) Allergic constitution or known allergy to the drugs or ingredients used. (8) Disabilities as prescribed by law include those who are deaf, dumb, blind, physically handicapped, mentally handicapped and mentally retarded. (9) Patients enrolled in other clinical trials within 3 months prior to the trial. (10) Patients who did not sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical effective rate;Visual Analogue Scale;Short form of 36 (SF-36); | — |
Secondary
| Measure | Time frame |
|---|---|
| Pelvic Hemodynamics;Serum Inflammatory Factors; | — |
Countries
China
Contacts
Public ContactLijuan Lu
Suzhou Traditional Chinese Medicine Hospital
Outcome results
None listed